Literature DB >> 1980693

Benzodiazepine dependency discontinuation: focus on the chemical dependency detoxification setting and benzodiazepine-polydrug abuse.

D E Smith1, M J Landry.   

Abstract

Benzodiazepines are commonly encountered in both psychiatric and chemical dependency treatment settings. However, in the chemical dependency setting, benzodiazepines are most frequently used as secondary drugs of abuse, and are most often found within a polydrug use pattern. Benzodiazepine use by the drug-abusing population consists of the combined use of benzodiazepines with other psychoactive drugs. They are used to medicate cocaine toxicity, as a secondary or tertiary drug to boost the effects of alcohol or heroin, and by those who have developed tolerance and dependence to sedative-hypnotic drugs. The presence of an anxiety disorder, a family history of addiction, or benzodiazepine polydrug use will significantly affect the type of withdrawal a patient will experience and its treatment course. Medical procedures accepted for benzodiazepine discontinuation include (1) graded reduction; (2) substitution of a long-acting benzodiazepine; and (3) phenobarbital substitution.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980693     DOI: 10.1016/0022-3956(90)90046-s

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  4 in total

1.  Changes in "withdrawal symptoms" following discontinuation of low-dose diazepam.

Authors:  P Hayward; J Wardle; A Higgitt; J Gray
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

2.  Diazepam alters cocaine self-administration, but not cocaine-stimulated locomotion or nucleus accumbens dopamine.

Authors:  Esther Y Maier; Ramon T Ledesma; Andrew P Seiwell; Christine L Duvauchelle
Journal:  Pharmacol Biochem Behav       Date:  2008-07-20       Impact factor: 3.533

3.  Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.

Authors:  Kenneth Blum; Marlene Oscar-Berman; Elizabeth Stuller; David Miller; John Giordano; Siobhan Morse; Lee McCormick; William B Downs; Roger L Waite; Debmalya Barh; Dennis Neal; Eric R Braverman; Raquel Lohmann; Joan Borsten; Mary Hauser; David Han; Yijun Liu; Manya Helman; Thomas Simpatico
Journal:  J Addict Res Ther       Date:  2012-11-27

Review 4.  Treatment of anxiety disorders.

Authors:  Borwin Bandelow; Sophie Michaelis; Dirk Wedekind
Journal:  Dialogues Clin Neurosci       Date:  2017-06       Impact factor: 5.986

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.